The Nourish report found that in just six months, 64% of patients who combined GLP-1 therapy with nutrition counseling lost at least 5% of their body weight, and 30% lost 10% or more
4 Challenges and future directions 4.1 Safety considerations The safety profile of dual or triple receptor agonists targeting GLP-1, GIP, and GCG receptors in the treatment of MASLD and related metabolic disorders warrants careful evaluation
The effect of citicoline supplementation on motor speed and attention in adolescent males
'There's a massive genetic component that drives the animal to be hungry all the time,' says Dr German
Phase 3: Expanding the Evidence Base Following encouraging Phase 2 findings, retatrutide advanced into the extensive TRIUMPH Phase 3 clinical program , one of the largest research initiatives ever undertaken for an investigational metabolic peptide
When calories become scarce, hanging onto muscle is de-prioritized